Therapeutic options for patients with relapsed SCLC are limited, and the prognosis in this setting remains poor. While clinical outcomes for frontline treatment have modestly improved with the introduction of immunotherapy, treatment in the second-line setting persists almost unchanged. In this review, current treatment options and recent advances in molecular biology are described. Emerging therapeutic options in this setting, and potential strategies to improve clinical outcomes of these patients are also addressed.

Moliner, L., Zhang, B., Lamberti, G., Ardizzoni, A., Byers, L.A., Califano, R. (2023). Novel therapeutic strategies for recurrent SCLC. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 186, 1-9 [10.1016/j.critrevonc.2023.104017].

Novel therapeutic strategies for recurrent SCLC

Lamberti, Giuseppe;Ardizzoni, Andrea;
2023

Abstract

Therapeutic options for patients with relapsed SCLC are limited, and the prognosis in this setting remains poor. While clinical outcomes for frontline treatment have modestly improved with the introduction of immunotherapy, treatment in the second-line setting persists almost unchanged. In this review, current treatment options and recent advances in molecular biology are described. Emerging therapeutic options in this setting, and potential strategies to improve clinical outcomes of these patients are also addressed.
2023
Moliner, L., Zhang, B., Lamberti, G., Ardizzoni, A., Byers, L.A., Califano, R. (2023). Novel therapeutic strategies for recurrent SCLC. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 186, 1-9 [10.1016/j.critrevonc.2023.104017].
Moliner, Laura; Zhang, Bingnan; Lamberti, Giuseppe; Ardizzoni, Andrea; Byers, Lauren A.; Califano, Raffaele
File in questo prodotto:
Eventuali allegati, non sono esposti

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/963301
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 5
  • ???jsp.display-item.citation.isi??? 4
social impact